Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01267188
Other study ID # NBI-98854-1001
Secondary ID
Status Completed
Phase Phase 2
First received December 21, 2010
Last updated April 18, 2011
Start date January 2011
Est. completion date March 2011

Study information

Verified date April 2011
Source Neurocrine Biosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective disorder.


Description:

This is a Phase 2, open-label, dose titration study to assess the efficacy and safety of three once daily (q.d.) doses (12.5, 25, and 50 mg) of NBI-98854 administered once daily for up to 12 days consisting of three treatment periods of 4 days each (Periods 1, 2, and 3). The starting dose will be 12.5 mg q.d. (Period 1), and this dose will be escalated to 25 mg q.d. (Period 2) and then to 50 mg q.d. (Period 3) based upon each subject's ability to tolerate NBI-98854. Progression to the next dose level will be based upon the subject's ability to tolerate the previous dose and the Investigator's review of adverse events and safety data. For subjects who do not tolerate a dose increase, the dose may be decreased to the dose that was previously administered (i.e., 25 mg to 12.5 mg, 50 mg to 25 mg) and continued at that dose for the remainder of the study treatment. Up to 10 medically stable subjects with schizophrenia or schizoaffective disorder who have moderate or severe symptoms of TD will be enrolled as outpatients.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Males or females (non-childbearing potential) aged 18 to 65 years (both inclusive).

- Have moderate or severe Tardive Dyskinesia symptoms (Total AIMS score of at least 9)

- Have a clinical diagnosis of schizophrenia or schizoaffective disorder.

- Receiving a stable dose of antipsychotic medication for a minimum of 30 days or have stable psychiatric status.

- Doses of concurrent medications and the conditions being treated have been stable for a minimum of 30 days and expected to remain stable during the study.

- Are in good general health and expected to complete the clinical study as designed.

- Have a body mass index (BMI) of 18 to 38 kg/m^2.

- Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion Criteria:

- Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening.

- Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start.

- Have a known history of neuroleptic malignant syndrome.

- Have a significant risk of suicidal or violent behavior.

- Receiving medication for the treatment of Tardive Dyskinesia

- Receiving any excluded concomitant medication as specified in the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NBI-98854
powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Neurocrine Biosciences

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of Tardive Dyskinesia symptoms Abnormal Involuntary Movements Scale (AIMS) and Clinical Global Impression - Global Improvement of TD (CGI-TD) scale 19 days
Secondary Number of Participants with Adverse Events following dosing with NBI-98854 Outcome assessment includes monitoring of:
Adverse events
Clinical laboratory tests
Vital signs
Physical examinations
12-lead electrocardiogram (ECG)
19 days
Secondary Evaluate pharmacokinetics of three doses of NBI-98854 Blood samples will be collected and analyzed to evaluate drug and metabolite plasma concentrations. 19 days
See also
  Status Clinical Trial Phase
Recruiting NCT02840760 - Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. N/A
Completed NCT01688037 - NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Phase 2
Completed NCT01391390 - Melatonin Treatment for Tardive Dyskinesia in Schizophrenia N/A
Withdrawn NCT03254186 - Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Phase 2/Phase 3
Completed NCT02291861 - Addressing Involuntary Movements in Tardive Dyskinesia Phase 3
Completed NCT02274558 - A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Phase 3
Completed NCT02198794 - Reducing Involuntary Movements in Participants With Tardive Dyskinesia Phase 3
Completed NCT01467089 - The Assessment of Movement Disorders Utilizing Live Two-Way Video N/A
Completed NCT04794413 - Pimavanserin Treatment in TS Early Phase 1
Recruiting NCT06011408 - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes N/A
Recruiting NCT05859698 - Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Phase 4
Active, not recruiting NCT02252380 - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders N/A
Terminated NCT00917293 - Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Phase 2
Completed NCT01543321 - Xenazine in Late Dyskinetic Syndrome With Neuroleptics Phase 3
Completed NCT02405091 - Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Phase 3
Completed NCT03176771 - Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Phase 2/Phase 3
Terminated NCT02524886 - Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia N/A
Completed NCT02195700 - Aim to Reduce Movements in Tardive Dyskinesia Phase 2/Phase 3
Completed NCT02736955 - Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Phase 3
Completed NCT03497013 - Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia N/A